DrugPatentWatch Database Preview
Litigation Details for Forest Laboratories Inc. v. Apotex Corp. (D. Del. 2014)
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Forest Laboratories Inc. v. Apotex Corp. (D. Del. 2014)
| Docket | Start Trial | Date Filed | 2014-02-14 |
| Court | District Court, D. Delaware | Date Terminated | 2016-02-16 |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | None | Referred To | |
| Parties | ACTAVIS LABORATORIES FL INC.; ADAMAS PHARMACEUTICALS INC.; ANCHEN PHARMACEUTICALS INC.; APOTEX CORP.; APOTEX INC.; CADILA HEALTHCARE LTD.; FOREST LABORATORIES HOLDINGS LTD.; FOREST LABORATORIES INC.; PAR PHARMACEUTICAL INC.; WATSON LABORATORIES INC. - FLORIDA; ZYDUS PHARMACEUTICALS (USA) INC. | ||
| Patents | 8,168,209; 8,173,708; 8,283,379; 8,329,752; 8,362,085; 8,598,233 | ||
| Attorneys | Damien Nicholas Tancredi; Dominick T. Gattuso; Francis J. Murphy , Jr.; Jack B. Blumenfeld; John K. Hsu; John W. Shaw; Joseph James Bellew; Maryellen Noreika; Sharick Naqi | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Forest Laboratories Inc. v. Apotex Corp.
The small molecule drugs covered by the patents cited in this case are Start Trial and Start Trial .
Details for Forest Laboratories Inc. v. Apotex Corp. (D. Del. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2014-02-14 | 1 | quot;the '708 patent"); 8,283,379 ("the '379 patent"); 8,329,752 ("the '…#39;009 patent, the '209 patent, the '708 patent, the '379 patent, the '752 patent, the … '009 patent, the '209 patent, the '708 patent, the ‘379 patent, the ‘752 patent, and the …#39;009 patent, the '209 patent. the '708 patent, the ‘3 79 patent, the '752 patent, the '…#39;009 patent, the '209 patent, the '708 patent, the '379 patent, the '752 patent, the | External link to document | |
| 2016-02-11 | 217 | infringement of U.S. Patent Nos. 8,039,009 (“the ‘009 Patent”); 8,168,209 (“the ‘209 Patent”); 8,173,708 (“…‘009 Patent, the ‘209 Patent, the ‘708 Patent, the ‘379 Patent, the ‘752 Patent, the ‘085 Patent, and…‘009 Patent, the ‘209 Patent, the ‘708 Patent, the ‘379 Patent, the ‘752 Patent, the ‘085 Patent, and…‘009 Patent, the ‘209 Patent, the ‘708 Patent, the ‘379 Patent, the ‘752 Patent, the ‘085 Patent, the…‘009 Patent, the ‘209 Patent, the ‘708 Patent, the ‘379 Patent, the ‘752 Patent, the ‘085 Patent, and | External link to document | |
| 2014-02-14 | 3 | Expiration of Patent: 8,039,009-03/24/2029; 8,168,209, 8,173,708, 8,283,379, 8,329,752, 8,362,085, 8,… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) … 16 February 2016 1:14-cv-00200 830 Patent None District Court, D. Delaware | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
